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Objective: To determine the prevalence of hepatitis C virus (HCV) among women seeking urgent gynecological
care.
Methods: Women were asked to complete a short self-assessment screening of HCV risk. Those answering yes
to any of the screening questions were offered HCV testing and were asked to complete a more detailed
questionnaire.
Results: Among the 125 women who completed the screening questionnaire, 80% (100) answered yes to one
or more of the screening questions. Of the 99 women who underwent testing, six (6.1%) were HCV
seropositive; a history of injection drug use was the only ﬁnding associated with HCV seropositivity (R.R 9.7:
95% CI 1.90–49.40).
Conclusions: Women seeking urgent outpatient gynecological care, particularly those who are injection drug
users, are at a substantial risk of HCV infection. A careful risk assessment should be completed in order to
identify women who should be offered HCV testing.
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INTRODUCTION
Hepatitis C virus (HCV) is the most common
blood-borne infection and is a leading cause of
chronic liver disease in the USA
1. Because
chronic HCV infection is often asymptomatic
for long periods of time, many people are not
aware that they are infected with HCV
2. The
purpose of this study was to determine the
prevalence of HCV infection among women
seeking urgent gynecological care.
MATERIALS AND METHODS
This study was conducted at Grady Memorial
Hospital, an inner city healthcare institution
serving the metropolitan Atlanta area. From
November 2001 to April 2002, 7210 women
patients presented at the Womens’ Urgent Care
Center for a broad range of emergent and urgent
gynecological services. During this time period,
English-speaking women presenting for non-
emergent outpatient care were initially given an
information sheet about HCV and a risk factor
assessment questionnaire. The information sheet
provided facts regarding infection, transmission,
prevention, and treatment of HCV. The risk
factor assessment questionnaire identiﬁed those
women with a history of sexually transmitted
disease, blood transfusion or organ transplant,
injection drug use, high-risk sexual behavior, or
hemodialysis. This screening process was based on
guidelines published by the Centers for Disease
Control and Prevention (CDC)
2.
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HCV infection identiﬁed in the screening ques-
tionnaire was offered HCV testing and asked to
complete a more detailed questionnaire. Written
informed consent was obtained from all partici-
pants in this study and ethical approval for this
study was obtained from the Human Investiga-
tions Committee at Emory University. HCV
infection was determined by the use of a second-
generation enzyme immunoassay (EIA, Abbott
Laboratories, Abbott Park, IL, USA) to detect
HCV antibodies.
Data analyses were performed with EpiInfo
version 6.0 (Centers for Disease Control and
Prevention, Atlanta, Georgia, USA). Unadjusted
relative risks with 95% conﬁdence intervals were
calculated based upon HCV seropositivity and
various potential risk factors including age, race,
history of sexually transmitted disease, history of
injection drug use, educational level, history of
tattoos, and current living situation.
RESULTS
Among the 125 women who completed the risk
factor assessment questionnaire, 80% (100) an-
swered yes to one or more of the screening
questions, indicating that they were at increased
risk of HCV. Of the 100 women at risk of HCV
infection, 67% admitted to a history of sexually
transmitted disease and 54% reported a history of
tattoos or body piercings.
Ninety-nine women were enrolled in the
study and one woman was excluded due to an
unsuccessful blood draw and subsequent inability
to ascertain HCV status. The characteristics of the
99 women completing the study are shown in
Table 1. Most of the participants were African-
American women between the ages of 20 and 30
years. More than one-third of the women
reported a history of each of the following
sexually transmitted diseases: chlamydia, gonor-
rhea, and trichomoniasis. None of the patients
reported that they were infected with human
immunodeﬁciency virus (HIV). When asked by a
multiple-choice question to identify the organ
that HCV affects most, 79 (90.8%) of the 87
women who answered the question identiﬁed the
liver as the correct answer. This was after the
women had been given an information sheet
about HCV as part of the screening process.
Of the 99 women tested for HCV infection,
six women were found to be HCV positive,
resulting in a prevalence of 6.1%. If it were
assumed that all women who did not report a risk
Table 1 Characteristics of 99 study participants
Age (years)
520 11 (11.1%)
21–30 61 (61.6%)
31–40 16 (16.2%)
440 11 (11.1%)
Race
African-American 89 (89.9%)
White 6 (6.1%)
Other 4 (4.0%)
Education
9
th Grade 20 (20.2%)
12
th Grade 61 (61.6%)
Associate/bachelor’s degree 11 (11.1%)
Graduate degree 2 (2.0%)
Other 5 (5.1%)
Living situation
Apartment 50 (50.1%)
House 38 (38.3%)
Other 11 (11.1%)
Sexually transmitted disease history
Chlamydia 38 (38.3%)
Gonorrhea 35 (35.3%)
Trichomoniasis 34 (34.3%)
Syphilis 6 (6.1%)
Herpes simplex virus 2 (2.0%)
More than one STD 33 (33.3%)
Drug use history
Marijuana 47 (47.4%)
Cocaine/crack 15 (15.2%)
Injection drugs 2 (2.0%)
History of one or more tattoos
Yes 53 (53.5%)
No 46 (46.5%)
History of blood transfusion
Yes 3 (3.0%)
No 96 (97.0%)
Answers to ‘which organ does HCV affect?’
Liver 79 (90.8%)
Lungs 4 (4.6%)
Kidneys 2 (2.3%)
Heart 1 (1.1%)
Brain 1 (1.1%)
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were HCV negative, the prevalence of HCV
infection would then be 4.8%. Of the six HCV
positive women, four were seen in the Gastro-
enterology Clinic at Grady Memorial Hospital for
follow-up. These four women were evaluated for
treatment options and each was counseled
regarding the avoidance of alcohol and other
potential liver toxins. Two women did not keep
appointments at the Gastroenterology Clinic and
no follow-up was obtained.
Potential predictors of HCV seropositivity
were evaluated, these factors included: those aged
less than 25 years; those of African-American
race; those with educational levels to less than
12th grade; those with living situations other than
an apartment or house; those with a history of
tattoos; those with a history of sexually trans-
mitted disease; and those with a history of
injection drug use. Relative risks with 95%
conﬁdence intervals were calculated (Table 2).
The only signiﬁcant risk factor that we identiﬁed
was a history of injection drug use (RR 9.7: 95%
CI 1.90–49.40).
DISCUSSION
The estimated prevalence of HCV in this
population of women seeking urgent gynecolo-
gical care at Grady was 4.8–6.1%. This is
substantially higher than estimates of HCV
prevalence among the general population. A
recent national seroprevalence study of approxi-
mately 20000 people in the USA found that the
overall prevalence of HCV infection was 1.8%
3.
Even among high-risk pregnant women, sero-
prevalence rates of 1–2% have been found. For
example, among a fairly high-risk population of
pregnant women at Parkland Hospital (i.e.
pregnant women cared for at Parkland Hospital
have a high incidence of risk factors for transmis-
sion of infectious diseases), the seroprevalence rate
of HCV antibody was 2.3%
4. Similarly, a
population-based sample of 1700 women residing
in low-income neighborhoods in northern Cali-
fornia found an HCV seroprevalence rate of
2.5%
5.
Our study conﬁrmed that injection drug use is
a primary risk factor for hepatitis C infection, as
has been found in previous studies
3,6. Although
our study did not show signiﬁcant associations
between high-risk sexual behavior and HCV
seropositivity, it was noted that high-risk sexual
behavior was the most common risk factor, as
demonstrated in the initial risk factor assessment.
In the CDC’s sentinel surveillance system, 15–
20% of patients with acute HCV have a history of
sexual exposure in the absence of other risk
factors
2.
The major limitation to our study was the small
number of women tested; therefore precise and
stable estimates of seroprevalence could not be
calculated. In addition, the participants represent a
convenience sample and therefore it is unknown
whether the women who were screened are
representative of the overall population of women
seeking urgent care at Grady. In our study
women without an identiﬁed risk factor were
not tested. Moreover, non-English speaking
women were excluded due to the inability to
properly complete the questionnaires and for
obtaining informed consent.
Table 2 Unadjusted relative risks between hepatitis C seropositivity and various risk factors
No. HCV positive Value 95% Conﬁdence interval
Age 525 years 1 0.19 0.02–1.55
History of STD 5 1.51 0.19–12.30
African-American race 5 0.56 0.07–4.34
History of injection drug use 1 9.70 1.90–49.4
History of tattoo 1 0.17 0.02–1.43
Education 512
th Grade 1 0.79 0.10–6.39
Living situation other than
home/apt.
00
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public health issue throughout the world, and
the substantial number of infected persons and
HCV-related deaths continues to bring this
disease to the forefront. Our recommendation is
that a careful HCV risk factor assessment be
performed for all of our patients, and individuals
at risk should be counseled and offered testing
for HCV. Like many other infectious diseases in
obstetrics and gynecology, HCV is probably an
important source of morbidity in our patient
population, and increased attention should be
focused on appropriate screening and preven-
tion.
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